Journal
VACCINE
Volume 34, Issue 30, Pages 3535-3541Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.04.083
Keywords
RSV; Immunization; Vaccination; Structure-based vaccine design; Fusion; Neutralization; Vaccine-enhanced illness; Bronchiolitis; Pneumonia; Infants; Elderly; Th2; Eosinophilia; Subunit vaccine; Vaccine vector; Wheezing; Asthma; Protein conformation; Epitope
Categories
Funding
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH
Ask authors/readers for more resources
Respiratory syncytial virus causes a significant public health burden, particularly in very young infants and the frail elderly. The legacy of enhanced RSV disease (ERD) from a whole formalin-inactivated RSV vaccine, and the complex biology of the virus and the neonate have delayed the development of effective vaccines. However, new insights into factors associated with ERD and breakthroughs in understanding the antigenic structure of the fusion (F) glycoprotein have increased optimism that vaccine development is possible. This has led to investment of time and resources by industry, regulatory authorities, governments, and nonprofit organizations to develop the infrastructure needed to make the advanced clinical development of RSV vaccine candidates a reality. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
